Stat3 Signaling in Pancreas Cancer
Stat3 Signaling in Pancreas Cancer
批准号:
8245261
负责人:
NIPUN B. MERCHANT
金额:
$30.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2017-03-31
关键词:
AddressAdenocarcinoma CellBiological MarkersBlood VesselsBlood flowCancer RemissionClinical TrialsCommunicationDataDesmoplasticDevelopmentDrug Delivery SystemsDrug resistanceEpidermal Growth Factor ReceptorErlotinibEventFailureFeedbackGene TargetingGenesGenetically Engineered MouseGoalsHeterogeneityHumanHypoxiaIndiumIntercellular FluidInterruptionKnowledgeLeadMaintenanceMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMediator of activation proteinMethodsModelingMolecularMutationNeoadjuvant TherapyNormal CellNutrientOncogenicOxygenPancreatic Ductal AdenocarcinomaPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPlayProtein Tyrosine KinaseResistanceRoleSignal PathwaySignal TransductionStat3 proteinTherapeuticTumor Angiogenesisangiogenesiscancer therapychemotherapyclinically relevantgemcitabineimaging modalityimprovedin vivoinhibitor/antagonistinsightloss of functionmouse modelneoplastic cellnovelnovel strategiespressureprognosticresponsesrc-Family Kinasestherapeutic targettranscription factortreatment strategytumortumorigenesis
中文摘要
描述(由申请人提供):迫切需要新的治疗胰腺导管腺癌(PDAC)的策略。该提案的长期目标是通过靶向PDAC肿瘤发生和内在耐药的关键介质来开发持久的癌症缓解策略。我们的中心假设是,致癌STAT3通路的激活代表(a)参与了内在耐药性,(b)构成了PDAC的潜在治疗靶点。总体目标是了解STAT3在PDAC中的组成性激活机制,并确定其下游生物学效应和临床相关性。通过功能获得和功能丧失的方法,我们将通过定义关键靶基因和建立STAT3、EGFR和Src激酶之间的功能相互作用来描述STAT3促进PDAC肿瘤发生的分子机制。我们将使用PDAC原位小鼠模型建立STAT3抑制的体内效应,并利用新的成像方式确定TME中STAT3信号相互作用的机制,以评估肿瘤血管生成、血流、缺氧和肿瘤药物在体内的传递。目的1:研究组成型激活STAT3在PDAC发病机制和内在耐药性中的功能作用。假设:STAT3转录网络在PDAC的发病机制和化疗耐药中起关键作用。目的1a将阐明PDAC中STAT3信号的组成性激活机制。Aim 1b将确定STAT3抑制和沉默对基本靶基因的生物学效应。Aim 1c将确定STAT3抑制和沉默是否克服了PDAC的耐药。Aim 1d将在一项国家临床试验中确定激活STAT3在接受新辅助吉西他滨和厄洛替尼治疗的PDAC患者中的预后意义。目的2:确定EGFR、Src和吉西他滨与STAT3的相互作用在克服PDAC化疗耐药中的作用。假设:STAT3联合靶向治疗将克服与PDAC中STAT3介导的化疗耐药相关的冗余信号通路和反馈回路。目的3:探讨STAT3信号在PDAC中与肿瘤微环境相互作用的机制。肿瘤微环境(tumor microenvironment, TME)在PDAC中起着至关重要的作用。假设:STAT3抑制将促进“血管正常化”和基质耗竭,从而增强药物向肿瘤的输送,从而改善治疗反应。成功完成这些特定目标将产生关于STAT3在PDAC中激活机制的重要新知识,并将进一步描述对EGFR, Src和STAT3的整合,功能关系和集体作用的理解,这将需要获得有效的PDAC多靶向治疗。提出的目标具有直接的翻译相关性,因为它们解决了pdac耐药的重要分子机制,并提供了用STAT3抑制剂靶向肿瘤细胞如何调节TME以提高化疗敏感性的见解。
英文摘要
DESCRIPTION (provided by applicant): There is a desperate need for novel treatment strategies for pancreatic ductal adenocarcinoma (PDAC). The long term goal of this proposal is to develop strategies for durable cancer remission by targeting critical mediators of PDAC tumorigenesis and intrinsic drug resistance. Our central hypothesis is that activation of the oncogenic STAT3 pathway represents (a) is involved in intrinsic drug resistance and (b) constitutes a potential therapeutic target for PDAC. The overall objective is to understand the mechanism of constitutive activation of STAT3 in PDAC and determine its downstream biologic effects and clinical relevance. Using gain- and loss-of-function approaches, we will delineate the molecular mechanisms by which STAT3 contributes to PDAC tumorigenesis by defining key target genes and establishing the functional interaction between STAT3, EGFR and Src kinase. We will establish the in vivo effects of STAT3 inhibition using an orthotopic mouse model of PDAC and define the mechanism of interaction of STAT3 signaling within the TME utilizing novel imaging modalities to assess tumor angiogenesis, blood flow, hypoxia and tumor drug delivery in vivo. This will be accomplished by the following specific aims: Aim 1: To investigate the functional role of constitutively activated STAT3 on the pathogenesis and intrinsic drug resistance of PDAC. Hypothesis: The STAT3 transcriptional network is critical in the pathogenesis and chemoresistance of PDAC. Aim 1a will elucidate the mechanism of constitutive activation of STAT3 signaling in PDAC. Aim 1b will determine the biologic effects of STAT3 inhibition and silencing on fundamental target genes. Aim 1c will determine if STAT3 inhibition and silencing overcomes drug resistance in PDAC. Aim 1d will determine the prognostic significance of activated STAT3 in PDAC patients treated with neoadjuvant gemcitabine and erlotinib in a national clinical trial. Aim 2: To determine the contributory roles of EGFR, Src and gemcitabine interaction with STAT3 in overcoming chemoresistance in PDAC. Hypothesis: Combined targeted therapy with STAT3 will overcome redundant signaling pathways and feedback loops associated with STAT3-mediated chemoresistance in PDAC. Aim 3: To determine the mechanism of interaction of STAT3 signaling on the tumor microenvironment in PDAC. The tumor microenvironment (TME) plays a critical role in PDAC. Hypothesis: STAT3 inhibition will promote "vascular normalization" and depletion of stroma, resulting in enhanced drug delivery to the tumor, leading to improved therapeutic response. Successful completion of these specific aims will yield significant new knowledge regarding the mechanism of STAT3 activation in PDAC and will further delineate an increased understanding of the integration, functional relationships and collective roles of EGFR, Src and STAT3 which will be needed to derive effective, multitargeted therapy for PDAC. The aims proposed have direct translational relevance as they address an important molecular mechanism of drug resistance in PDACs and offer insight into how targeting tumor cells with STAT3 inhibitors may modulate the TME to improve sensitivity to chemotherapy.
PUBLIC HEALTH RELEVANCE: The heterogeneity of genetic alterations associated with most human cancers, makes it highly unlikely that a "one size fits all" approach will be effective. It is becoming increasingly clear that many of the aberrant signaling pathways commonly seen in cancer lead directly to central regulators of expression and function of a variety of genes that are fundamental to events of tumor development and progression. Delineating an increased understanding of the integration, functional relationships and collective roles of these critical mediators will be essential to develop strategies for durable cancer remission.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Research Training Program in Surgical Oncology
-
批准号:9209664
-
项目类别:
-
资助金额:$17.27万
-
财政年份:2016
-
负责人:NIPUN B. MERCHANT
-
依托单位:
Research Training in Surgical Oncology
-
批准号:10704518
-
项目类别:
-
资助金额:$33.89万
-
财政年份:2016
-
负责人:NIPUN B. MERCHANT
-
依托单位:
Research Training in Surgical Oncology
-
批准号:10455449
-
项目类别:
-
资助金额:$33.07万
-
财政年份:2016
-
负责人:NIPUN B. MERCHANT
-
依托单位:
Research Training Program in Surgical Oncology
-
批准号:9769662
-
项目类别:
-
资助金额:$22.42万
-
财政年份:2016
-
负责人:NIPUN B. MERCHANT
-
依托单位:
Research Training Program in Surgical Oncology
-
批准号:9352298
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2016
-
负责人:NIPUN B. MERCHANT
-
依托单位:
Research Training in Surgical Oncology
-
批准号:10200455
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2016
-
负责人:NIPUN B. MERCHANT
-
依托单位:
Reprogramming the Tumor Microenvironment in Pancreas Cancer to Enhance Immunotherapy
-
批准号:10328894
-
项目类别:
-
资助金额:$37.61万
-
财政年份:2012
-
负责人:NIPUN B. MERCHANT
-
依托单位:
Reprogramming the Tumor Microenvironment in Pancreas Cancer to Enhance Immunotherapy
-
批准号:10083193
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2012
-
负责人:NIPUN B. MERCHANT
-
依托单位:
Stat3 Signaling in Pancreas Cancer
-
批准号:8441523
-
项目类别:
-
资助金额:$30.43万
-
财政年份:2012
-
负责人:NIPUN B. MERCHANT
-
依托单位:
海外基金